Reviews
Average rating: 4/5
Physician ( 1 )
-
5
-
4
-
3
-
2
-
1
Average rating: 4.00/5
Total Reviews: 1
-
5
-
4
-
3
-
2
-
1
Donanemab has demonstrated a ~30% slowing of cognitive and functional decline in patients with early Alzheimer’s disease, particularly those with low to medium tau pathology. Like other drugs in its class, it carries risks of amyloid-related imaging abnormalities (ARIA), including brain swelling and microhemorrhages, requiring regular MRI monitoring. Its use is best reserved for carefully selected patients with confirmed amyloid pathology, balancing modest clinical benefits against potential safety concerns.
0